AMPLIFY rollout by Myriad Genetics lifts Prequel Prenatal screen to near perfect detection rate

AMPLIFY rollout by Myriad Genetics lifts Prequel Prenatal screen to near perfect detection rate
Myriad Genetics AMPLIFY boosts accuracy

Myriad Genetics has marked the six-year anniversary of its AMPLIFY technology, which transformed prenatal cell-free DNA screening by achieving a 99.9 percent accuracy rate for patients tested at 10 weeks' gestation.

The integration of AMPLIFY into the Prequel Prenatal screen has set a new industry standard, offering highly reliable results for early prenatal testing and improving confidence for patients and clinicians alike. The advancement underscores a pivotal moment for reproductive health screening, reflecting sustained innovation in genetic testing platforms.

Myriad Genetics has previously introduced AI enhancements to its active surveillance test to improve management in urology and prostate cancer care, according to an earlier announcement. The company also plans to launch the Prolaris plus AI Test, combining molecular scores with AI digital pathology for prostate cancer diagnosis, as stated in a separate release. These developments demonstrate Myriad's ongoing expansion in genetic and diagnostic testing platforms.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.